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Abstract
Background: Accurate molecular diagnosis of monogenic non-autoimmune neonatal diabetes mellitus (NDM) is critical for
patient care, as patients carrying a mutation in KCNJ11 or ABCC8 can be treated by oral sulfonylurea drugs instead of insulin
therapy. This diagnosis is currently based on Sanger sequencing of at least 42 PCR fragments from the KCNJ11, ABCC8, and
INS genes. Here, we assessed the feasibility of using the next-generation whole exome sequencing (WES) for the NDM
molecular diagnosis.
Methodology/Principal Findings: We carried out WES for a patient presenting with permanent NDM, for whom mutations
in KCNJ11, ABCC8 and INS and abnormalities in chromosome 6q24 had been previously excluded. A solution hybridization
selection was performed to generate WES in 76 bp paired-end reads, by using two channels of the sequencing instrument.
WES quality was assessed using a high-resolution oligonucleotide whole-genome genotyping array. From our WES with
high-quality reads, we identified a novel non-synonymous mutation in ABCC8 (c.1455G.C/p.Q485H), despite a previous
negative sequencing of this gene. This mutation, confirmed by Sanger sequencing, was not present in 348 controls and in
the patient’s mother, father and young brother, all of whom are normoglycemic.
Conclusions/Significance: WES identified a novel de novo ABCC8 mutation in a NDM patient. Compared to the current
Sanger protocol, WES is a comprehensive, cost-efficient and rapid method to identify mutations in NDM patients. We
suggest WES as a near future tool of choice for further molecular diagnosis of NDM cases, negative for chr6q24, KCNJ11 and
INS abnormalities.
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Introduction
Neonatal diabetes mellitus (NDM) is a rare monogenic form of
non-autoimmune diabetes which affects 1 in ,300,000 live births
and is diagnosed before six months of age [1,2,3]. Approximately
half of the NDM cases are transient (TNDM) but can ultimately
relapse. In contrast, permanent NDM (PNDM) cases need
continual treatment from diagnosis [1,2,3]. More than half of
both forms of NDM cases have been elucidated, so far, and it
appears that the genetic aetiologies of NDM are quite heteroge-
neous. Indeed, although the majority of TNDM cases have an
abnormality in chromosome 6q24 and the other most frequent
causes of NDM are missense mutations in the pancreatic b-cell
KATP channel genes KCNJ11 and ABCC8, and in the preproinsulin
gene, NDM has been linked to numerous other genetic causes
including point mutations in GCK, GLIS3, EIF2AK3, PDX1,
PTF1A, SLC2A2, HNF1B or FOXP3 [1,2,3].
Even if the presence of specific clinical features (e.g. relatively late
age of onset, pancreas agenesis, developmental delay, renal failure,
anaemia, thyroid disease, cardiac disorders…) or a family history of
diabetes or consanguinity may suggest potential molecular aetiolo-
gy(ies) for NDM, a molecular genetic diagnosis is crucial as it can
predict the most appropriate treatment and genuinely improve
qualityoflife[3].ThemoststrikingexampleisseenforNDMpatients
w i t ham u t a t i o ni nt h eK ATP channel genes, who can be treated
effectively with oral sulfonylureas that directly bind the SUR1
regulatory subunit of the channel, rather than requiring life-long
insulin therapy which usually provides poor glycemic contol [4,5,6].
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to establish a personal molecular genetic diagnosis for family
counselling and to plan personalized pharmacotherapy. When
severe hyperglycaemia is detected in a neonate, it is difficult to
predict whether NDM will be transient or permanent. If the young
patient does not have extrapancreatic features or a family history
of diabetes (especially in a consanguineous context), it is suggested
to first search for a chromosome 6q24 abnormality or for a
KCNJ11 mutation, as these NDM aetiologies are the most
frequent, and then for mutations in ABCC8 and INS if the first
tests are negative [1,3]. As KCNJ11, ABCC8 and INS altogether
represent 42 coding exons, sequencing these genes using the
standard Sanger protocol is obviously tedious, long and costly. If
this first set of gene sequencing is negative, further molecular
analysis of the other NDM genes is generally not performed. This
current approach to molecular diagnosis of NDM provides only a
limited sequencing of the known NDM genes and no assessment of
possible modifier genetic loci elsewhere in the genome: a more
comprehensive cost efficient methodology to scrutinize every new
NDM case is necessary.
In the present study, we demonstrate the feasibility of next-
generation whole exome sequencing (WES) for the molecular
diagnosis of a patient with NDM without any extrapancreatic
features or family history of diabetes. Despite previous negative
Sanger sequencing of ABCC8 by a hospital laboratory, we
identified a novel non-synonymous mutation in this gene through
WES. We show that this cutting-edge novel technology is more
comprehensive, less labour intensive and thus cheaper for NDM
diagnosis than standard sequencing protocols.
Results
The patient’s clinical record reported that he has developed
severe hyperglycemia, ketoacidosis and weight loss at two months
of age. HLA typing showed neutral alleles for type 1 diabetes
mellitus susceptibility. Pancreas ultrasound scan was normal and
the patient did not show any specific extra-pancreatic clinical
features. He was firstly treated with continuous subcutaneous
insulin infusion during two years with rather low dose of insulin
(,0.5 units/kg/day) for a pretty good metabolic control (A1C
,8.5%). He was then switched with a basal-bolus scheme for
technical adverse outcome. The patient is currently 20 years old.
He is treated with 1.1 units/kg/day of insulin, with A1C values
ranging between 8 and 9%. He always had an attention disorder
and a learning disability without obvious motor symptoms or
epilepsy.
After target enrichment, the whole exome DNA library from
the patient was sequenced in 76 base-pairs (bp) paired-end reads,
using two channels of the sequencing instrument. The WES
generated 34,600,000 bp of nucleotide sequences mapping once to
the targeted exome, which achieved a mean coverage of 1226of
the target exome. WES identified 55,202 targeted DNA variants
from the reference human genome sequence NCBI36/hg18, of
which 4,463 were novel compared to the public database
dbSNP130 and the eight HapMap exomes sequenced by Ng
et al. [7] (Table 1). More specifically, we found 407 genes with one
or more novel mutations including missense coding SNPs, gains of
STOP codon and frameshift mutations (Table 1).
To validate our WES data and analysis protocol, the patient’s
DNA was genotyped using an Illumina Human1M-Duo array,
which contains 8,500 single nucleotide polymorphisms (SNPs)
located in exons captured by the Agilent SureSelect technology.
WES identified 7,969 exomic SNPs present on the genotyping
array (93.8%), and showed high concordance rates for homozy-
gous and heterozygous calls (100% and 99.5% and respectively).
By using only one channel of the sequencing instrument, the
generated sequence achieved a mean coverage of 656of the target
genome and 88.9% of the exomic SNPs present on the genotyping
array were identified. These results would suggest that our WES
based on the use of two channels of the genome analyzer has a low
Table 1. Number of mutations identified through the WES analysis of DNA sample from the PNDM patient.
Sample PNDM patient
Total targetted SNPs (Novel
*) 55,202 (4,463)
Homozygous SNPs Total SNPs (Novel
*) 22,030 (589)
Concordance
* (%) 100
Sensitivity
{ (%) 91.8
Heterozygous SNPs Total SNPs (Novel
*) 33,172 (3,872)
Concordance
{ (%) 99.5
Sensitivity
{ (%) 95.1
Synonymous coding SNPs Homozygous (Novel
*) 3,262 (14)
Heterozygous (Novel
*) 4,780 (277)
Missense coding SNPs (a) Homozygous (Novel
*) 2,907 (18)
Heterozygous (Novel
*) 4,264 (430)
Gains of STOP codon (b) Homozygous (Novel
*) 16 (0)
Heterozygous (Novel
*) 30 (7)
Insertions or deletions (c) Homozygous (Novel
*; Novel frameshift) 1,748 (951; 0)
Heterozygous (Novel
*; Novel frameshift) 409 (284; 0)
Genes with one or more (a),(b) or (c) mutations (Novel
*) 4,495 (407)
*Novel: a novel mutation means that it is not present in the public database dbSNP130 and the eight HapMap exomes sequenced by Ng et al. [7].
{Concordance: % of similar allele assignment among exomic mutations detected on the Illumina Human1M-Duo array and those discovered by WES.
{Sensitivity: % of exomic mutations present on the Illumina Human1M-Duo array that have been discovered by WES.
doi:10.1371/journal.pone.0013630.t001
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necessary to achieve accurate molecular diagnosis for patients
presenting with monogenic disorders.
In 2004, single-stranded Sanger sequencing analysis of the
patient’s DNA by a hospital unit showed no evidence for coding
mutations in ABCC8. Also, no abnormalities in KCNJ11, INS and
chromosome 6q24 were reported by the molecular diagnostic
laboratory of Robert Debre ´ Hospital (Paris, France). Since these
assessments were performed six years ago, we checked again for
mutations in these three genes as well as in all other genes known
to be involved in monogenic forms of diabetes. Unexpectedly, we
identified a novel heterozygous non-synonymous mutation
c.1455G.C/p.Q485H in the 9
th exon of ABCC8. Based on this
startling result, we used a standard Sanger sequencing protocol, to
study the patient’s DNA sample available in the CNRS-
UMR8199 unit (Lille, France) as well as the sample stored at
the Robert Debre ´ hospital (Paris, France). In both cases, we
identified the p.Q485H mutation in ABCC8, confirming our WES
results. In addition, retrospective re-examination of the data
generated six years ago indicated that the p.Q485H mutation was
present in the original ABCC8 exon 9 sequences (chromogram).
The ABCC8 p.Q485H mutation was not found in 348 French
nondiabetic individuals or in the patient’s mother, father and
young brother, all of whom are normoglycemic. The p.Q485H
mutation affects an amino acid that is located in the transmem-
brane domain 1 (TMD1) of the ABCC8/SUR1 core; and that is
highly conserved across species (Rhesus, Mouse, Dog, Rabbit,
Elephant, Opossum, Platypus, Chicken, Lizard, Stickleback,
X_Tropicalis, Tetraodon) according to the UCSC (NCBI/hg18)
comparative genomics alignment pipeline (http://www.bx.psu.
edu/miller_lab/). We evaluated the possible functional signifi-
cance of the p.Q485H mutation by the PolyPhen-2 (Polymor-
phism Phenotyping v2) software which uses sequence- and
structure-based criteria to predict the putative impact of point
mutations on the structure and function of human proteins [8]: the
p.Q485H mutation is predicted ‘probably damaging’ with a score
of 0.999 (the score of 1 indicating the most damaging mutation).
Following the identification of this ABCC8 mutation in the
patient’s DNA, a switch from insulin to oral sulfonylurea treatment
will be tried soon at Necker Hospital (Paris, France).
Discussion
In the present study, we demonstrate for the first time that WES
can be seen as a relevant alternative for molecular diagnosis of
NDM. Since an accurate molecular diagnosis for this condition
can lead to very dramatic improvements in patient care,
development of reliable and cost efficient methods for quick and
accurate DNA analysis are of major interest.
Currently, patients with NDM are evaluated using Sanger
sequencing, which is far more expensive per sequenced base-pairs
than WES. Indeed, the standard sequencing of a single PCR
fragment costs 67.50J ($82) for the only French hospital
laboratory specialized in NDM molecular diagnosis (Robert
Debre ´ hospital, Paris). This price includes consumables, equip-
ment amortization, personnel salary and hospital overhead costs.
Therefore, the total cost for the French National Insurance for the
sequencing of KCNJ11, ABCC8 and INS alone, which requires 42
PCR fragments is 2,835J ($3,440; ,0.45J or ,$0.55 per bp). In
comparison, the all inclusive cost of WES for NDM, which will
detect mutations in KCNJ11, ABCC8 and INS as well as rarer
genetic aetiologies of NDM, is currently 3,274J ($4,146;
,,0.001J or $ per bp) per sample, by performing a sequencing
on two channels and in 76 bp paired-end configuration (CNRS-
UMR8199, Lille, France). Moreover, it is very likely that WES
cost will fall in next months towards 2,000J ($2,528) or even less.
We believe that the WES protocol is less labour intensive and
time-consuming than the standard Sanger protocol for genetically
heterogeneous disorders requiring several large genes to be
screened. A WES run involving four DNA samples can be
completed in two weeks, including the time required to analyse the
data, which is comparable to the time required by current Sanger
sequencing of ABCC8 only with its 39 exons. The p.Q485H
mutation was missed six years ago by the research assistant in
charge of the sequence reading. Although we can assume that
mutation detection bio-informatics tools were less efficient a few
years ago (the hospital laboratory used the PhredPhrap software in
2004) and that current methods are more accurate, the Sanger
protocol and specially the semi-automated reading of sequence
traces is always laborious and demanding (thus expensive), and a
double-check of sequence readings by two different persons is
performed in several French diagnostic laboratories in order to
avoid any errors in the mutation identification process.
WES method is not only a cost-effective tool for molecular
diagnosis; it should be also seen as an excellent tool for further
genetic research and identification of novel causal mutations.
Indeed, in the French NDM cohort, half of PNDM cases are still
not elucidated [9,10]. Classical linkage analyses are generally not
successful as many NDM mutations occur de novo or are not fully
penetrant. Most NDM genes have been found via candidate gene
analyses but this approach has now reached its limits [11].
However, WES typically yields thousands of ‘novel’ genetic
variants (i.e. not yet present in human genome variants databases).
Therefore, the identification of truly causal variants would be
strongly facilitated by the development of a high quality WES
database of novel mutations found in both elucidated cases or in
cases of unknown aetiology as well as in controls coming from
same ethnicity. WES would also permit the identification of
putative NDM modifier genes, a very challenging task for targeted
gene analysis.
We are quite confident that the p.Q485H mutation is likely to
be functional given the non ambiguous prediction of its putative
damaging effect. In addition, the clinical data from the patient fit
well with the features of PNDM linked to a ABCC8 mutation (e.g. de
novo mutation associated with very early-onset of the disease and
attention disorder) [4,12].
We believe that other NDM patients should be assessed with the
same protocol as DNA quality may change the WES accuracy.
Also, our DNA capture was not totally perfect as we could miss
approximately 6% of exomic SNPs present in the high-resolution
oligonucleotide genotyping array. Furthermore, the exomic
coverage was not homogeneous between NDM genes (Table 2),
thus we could suspect that the WES accuracy would not be the
same for all NDM genes. Therefore, despite high WES mean
coverage and elevated rates of both concordance and sensitivity in
mutation detection, it is also necessary to assess and to verify the
homogeneity of the target capture, specially in the genes of interest
that have to be screened for molecular diagnosis (Table 2).
Knowing that the capture technology is improving day after day
(by enriching exomic loci poorly captured with the previous kits),
our present study suggests that it will be possible to soon update the
protocols for molecular diagnosis of NDM [3,13]. We propose that
after discovery of severe hyperglycemia in a neonate who is negative
for serological markers of type 1 diabetes, a preliminary assessment
of abnormalities of chromosome 6q24 can be performed (as at this
stage, it is too early to guess NDM will be permanent or transient)
followed by the search of a mutation in both KCNJ11 and INS using
Sanger sequencing as these two genes can be easily and quickly
WES and NDM Diagnosis
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DNA which is the most comprehensive way to fully explore the
molecular causes of this NDM case.
Materials and Methods
Study participant and DNA samples
For WES, we selected a patient of European origin, diagnosed
with PNDM who was referred to the French Network for the
Study of Neonatal Diabetes Mellitus [9]. He was born from non
consanguineous parents and had no intra-uterine growth retarda-
tion (birth weight 2,900 g/birth length 50 cm at 40 gestational
weeks). He underwent a thorough clinical examination and his
medical records were reviewed. Assessment of neurological
outcome was also performed. Initial diagnostic testing for
mutations in KCNJ11, ABCC8 and INS, and for chromosome
6q24 abnormalities was negative. DNA samples from the patient’s
parents and his young brother were available for genetic testing.
Ethics Statement
The study was approved by the local ethics committees
(Assistance Publique – Ho ˆpitaux de Paris, ClinicalTrials.gov
Identifier: NCT00610038), and both parents gave written
informed consent for the genetic testing of their child.
Targeted capture and massive parallel sequencing
Approximately 187,000 coding exons from 3 mg of genomic DNA
from the patient were captured using the Agilent SureSelect Human
All Exon kit, following the manufacturer’s protocols. Briefly, DNA
was sheared by acoustic fragmentation (Covaris) and purified using
the QIAquick PCR Purification Kit (Qiagen). The quality of the
fragmentation and purification was assessed with the Agilent 2100
Bioanalyzer. The fragment ends were repaired and adaptors were
ligated to the fragments (NEBNextDNA sampleprep, New England
Biolabs).TheresultingDNAlibrarywaspurified usingtheQIAquick
PCR Purification Kit, amplified by PCR and captured by hybri-
dization to the biotinylated RNA library ‘‘baits’’ (Agilent). Bound
genomic DNA was purified with streptavidincoated magnetic Dynal
beads (Invitrogen) and re-amplified. The whole-exome DNA library
was sequenced on the Illumina Genome Analyzer IIx in 76 bp
paired-end reads and using two channels.
Read mapping, variant analysis and quality test of the
sequencing protocol
Sequence reads were mapped to the reference human genome
(UCSC NCBI36/hg18) using the ELANDv2 software (Illumina).
Variant detection was performed with the CASAVA software
(version 1.6, Illumina) and filtered to fit a CASAVA quality
threshold $10 and depth of $86CASAVA filters duplicate reads
and reads without matched pairs.
A genomic DNA sample from the patient was genotyped on the
Illumina Human 1M-Duo DNA Analysis BeadChips (with a call
rate of 99.3%) as previously described [14]. We assessed the rate of
exomic single nucleotide polymorphisms (SNPs) present on the
array that were identified by WES and we calculated the
concordance between the two methods.
Mutation validation
The p.Q485H mutation identified via WES was confirmed
using the Sanger method. Primer sequences and PCR conditions
are available upon request to authors. The PCR fragment fitting
the 9
th exon of ABCC8 was sequenced using a standard protocol
and the automated 3730xl DNA Analyser (Applied Biosystems).
Electrophoregram reads were assembled and analysed with the
Variant Reporter software (Applied Biosystems).
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Table 2. Details on exomic sequencing depth in NDM genes, obtained through the WES of the PNDM patient.
NDM genes Chromosome Start End
Number
of coding
exons
Exomic
size (bp)
Number of
mapped
76 bp
exomic
reads
Mean exomic
coverage
% of sequenced exomic genes
according to several depth
thresholds
$86 $206 $506 $1006
KCNJ11 chr11 17365042 17366214 1 1173 984 57.16 100 88.7 50.5 13.6
ABCC8 chr11 17371114 17454899 39 4746 6235 90.56 94.6 85.0 54.5 31.6
INS chr11 2137658 2138777 2 333 97 24.46 87.1 65.8 0 0
GCK chr7 44164197 44159587 12 2012 1055 46.16 70.8 44.1 19.0 14.4
GLIS3 chr9 3818272 4115864 9 2328 3672 130.46 84.8 79.4 67.8 39.9
EIF2AK3 chr2 88638369 88707907 17 3351 9507 214.16 92.2 92.0 87.1 81.4
PDX1 chr13 27392276 27396838 2 852 179 27.26 40.3 24.5 3.9 0
PTF1A chr10 23521466 23522840 2 986 405 59.96 38.8 36.4 26.3 7.0
SLC2A2 chr3 172198386 172227153 11 1575 3669 170.96 99.6 99.2 88.8 69.8
HNF1B chr17 33121488 33178988 9 1674 2089 94.56 93.3 83.4 53.5 34.5
FOXP3 chrX 48994739 49001906 11 1296 402 25.66 69.7 51.9 13.8 0
doi:10.1371/journal.pone.0013630.t002
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